fbpx

News in Gastric Cancer

News from around the world, curated by the Gastric Cancer Foundation.
nivolumab opdivo

Phase 3 Trial Evaluating Opdivo (nivolumab) as Adjuvant Therapy for Patients with Resected Esophageal or Gastroesophageal Junction Cancer, Meets Primary Endpoint of Disease-Free Survival

In a trial, Bristol Myers Squibb’s Opdivo improved disease-free survival in patients with esophageal cancer who had undergone surgery and chemotherapy.

Read Source
DonateMore InfoDonateMore Info
We cannot gather at a gala event this year, but a pandemic cannot stop us from joining together to ensure that the search to find a cure for gastric (stomach) cancer continues.

Join with us to fuel the next wave of progress.

Every contribution moves us closer to a cure.
We cannot gather at a gala event this year, but a pandemic cannot stop us from joining together to ensure that the search to find a cure for gastric (stomach) cancer continues.

Join with us to fuel the next wave of progress.

Every contribution moves us closer to a cure.
X